niclosamide / Generic mfg. - LARVOL DELTA

Dose-Response Relationship of Niclosamide and Metformin Combination in ApcMin/+ Mice: An Integrated In Vivo and Pharmacokinetic Modeling Study. (PubMed, Gut Liver) - "Notably, the predicted metformin plasma Cmax remained within a safe therapeutic window at the 100 mg/kg combination dose but exceeded a safety threshold at 200 mg/kg. By integrating in vivo efficacy testing with quantitative modeling, our study identified the 100 mg/kg combination of niclosamide and metformin as the optimal dose for chemoprevention in a murine FAP model, providing a strong rationale for future clinical translation in FAP management."

Journal • PK/PD data • Preclinical • Colonic Polyps • Colorectal Cancer • Genetic Disorders • Oncology • Solid Tumor • APC

Niclosamide suppresses gastric cancer progression through YTHDF2 inhibition-affected lactate metabolic reprogramming. (PubMed, iScience) - "Our research revealed comprehensive metabolic alterations in gastric cancer, including upregulated lactate metabolism that promotes tumorigenesis via the lactate shuttle. Niclosamide targets the m6A methylation regulatory protein YTHDF2, which influences genes related to metabolism, indicating its potential as a prospective treatment for GC."

Journal • Gastric Cancer • Metabolic Disorders • Oncology • Solid Tumor • YTHDF2

Niclosamide and Palbociclib Act Synergistically to Reduce Cholangiocarcinoma Cell Viability In Vitro and Inhibit Tumour Growth in a Mouse Model. (PubMed, Cancers (Basel)) - "Interestingly, the CDK4/6 kinase inhibitor Palbociclib selectively reduces the viability of cholangiocarcinoma cell lines compared to normal biliary epithelial cells and, importantly, Palbociclib synergises with Niclosamide to reduce cholangiocarcinoma cell viability in vitro as well as to reduce tumour growth in a mouse xenograft model. These preclinical results suggest that the combination of Niclosamide and an inhibitor of CDK4/6 is worthy of clinical evaluation as a potential treatment for this disease."

Journal • Preclinical • Biliary Cancer • Cholangiocarcinoma • Liver Cancer • Oncology • Solid Tumor

A novel graphene oxide-niclosamide hybrid as a potent antiviral agent against dengue virus serotype 3. (PubMed, Colloids Surf B Biointerfaces) - "The synergistic effect between GO and niclosamide contributed to the inhibition of viral replication. These findings highlight GO-Nic potential as a novel antiviral candidate for dengue infection."

Journal • Dengue Fever • Infectious Disease

Novel Therapeutic Strategy for Renal Cell Carcinoma: Niclosamide Enhances Sunitinib Efficacy via DNA Repair and Cell Cycle Pathways. (PubMed, Int J Mol Sci) - "Tyrosine kinase inhibitors (TKIs), such as sunitinib and sorafenib, are standard treatments for renal cell carcinoma (RCC). RNA sequencing (RNA-seq) and bioinformatic analyses showed that niclosamide modulated critical pathways, including BRIP1- and FANCA-mediated DNA repair and E2F2-regulated cell cycle progression. These findings provide proof-of-concept that niclosamide enhances TKI efficacy through modulation of DNA repair and cell cycle pathways, supporting the rationale for DNA damage response (DDR)-targeted combination strategies in RCC."

Journal • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • BRIP1 • E2F2 • FANCA

Succinate Dehydrogenase-Deficient Cancer Cells Have Increased Susceptibility to Ym155 Induced DNA Damage. (PubMed, bioRxiv) - "Given the reduced ATP-generating capacity of SDHB -KO cells, we hypothesized they would be uniquely sensitive to futile cycle induction with mitochondrial ionophores (2,4-Dinitrophenol (2-DNP), BAM15, Niclosamide, Nitazoxanide). Thus, the accumulation of succinate in SDH-deficient tumors inhibits KDM4 activity, impairs DNA repair and yields enhanced susceptibility to Ym155-induced reactive oxygen species (ROS) generation. The identified intrinsic susceptibilities of SDHB -deficient cancers has the potential to be therapeutically leveraged."

Journal • Gastrointestinal Cancer • Gastrointestinal Stromal Tumor • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Sarcoma • Solid Tumor • SDHB

Dissecting macrophage heterogeneity in ulcerative colitis: Single-cell analysis and functional validation of S100A4 as a therapeutic target. (PubMed, Int Immunopharmacol) - "This study provides a comprehensive single-cell landscape of macrophage heterogeneity in UC, identifying S100A8+ and IL1B+ macrophages as key mediators of mucosal inflammation. Integrative analysis pinpointed S100A4 as a robust diagnostic and therapeutic candidate, with experimental validation underscoring its translational potential. These findings offer new insights into macrophage-driven pathogenesis and open avenues for targeted UC therapies."

Heterogeneity • Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Mucositis • Ulcerative Colitis • APOE • IL1B • S100A4 • S100A6 • S100A8

Targeting Mitochondrial Metabolism to Promote Viral Mimicry and Type I Interferon Response in Acute Myeloid Leukemia (ASH 2024) - "Transcriptomic analysis of persisting AML cells post-induction therapy (cytarabine and doxorubicin) in an MLL-AF9 immune-competent C57BL/6 mouse model revealed that the persisting AML cells were negatively enriched for type-I IFN response and positively enriched for myc, oxidative phosphorylation, unfolded protein response and fatty acid metabolism...We discovered that Artesunate (ART; an anti-parasitic drug used to treat malaria), and Niclosamide (NA; an anti-helminthic drug used to manage tapeworm infections), elicited ISRE activity in a dose-dependent manner...Treatment of AML cells with ART, NA, or the BH3 mimetic Venetoclax (mitochondrial inhibitor used in the management of AML) promoted the leakage of mitochondrial DNA in the cytosol; however, only NA and ART increased the activation of IFN-stimulated genes, highlighting that not all mitochondria-targeting agents act in the same way...We propose that ART can be repurposed as a potential STING agonist. Further..."

Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Leukemia • Malaria • Oncology • CD4 • CD8 • IFNA1 • STAT1 • STAT2

Dietary Sarcodia suieae Hydrocolloid Supplementation Elevates Quercetin Levels and Modulates Metabolic and Immune Pathways in the Hepatopancreas of Macrobrachium rosenbergii: Insights from Integrated Omics Analyses. (PubMed, Dev Comp Immunol) - "Conversely, certain amino acids like L-Allothreonine and L-Proline, and compounds such as 5-Aminopentanoic acid and Niclosamide, were significantly downregulated...The enrichment of autophagy and apoptosis pathways at higher concentrations suggests a significant impact on cellular turnover and stress responses, potentially contributing to adaptation or maintaining cellular homeostasis under the influence of the hydrocolloid. These integrated omics findings elucidate the complex molecular mechanisms by which S. suieae hydrocolloid influences the hepatopancreatic health and metabolic regulation in M. rosenbergii, providing valuable insights for the development of novel functional feeds in sustainable aquaculture."

Journal

Proteomics-Based Approach Recognize Unique Expression Profiles in Adult Acute Monocytic/Monoblastic Leukemia: Implications for Prognostication and Drug Repurposing (ASH 2024) - "In the case of S100A4, which is highly expressed in both clusters compared to normal bone marrow, inhibitors (e.g. niclosamide) are under clinical trial for solid malignancies...Protein signatures were prognostic in UV/MV analyses, suggesting that stratification via proteomics could potentially guide therapy. We further propose that targeting highly active proteins (e.g. S100A4) with already existing drugs might improve AMoL outcomes of patients with poor responses to current therapies."

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Solid Tumor • CD34 • CDKN1B • ERN1 • ETS1 • FLT3 • GATA2 • KMT2A • NOTCH1 • NPM1 • RUNX1 • S100A4 • TP53 • ZAP70

TMEM16E and TMEM16F Regulate the Generation and Procoagulant Activity of Extracellular Vesicles during Endothelial Cell Inflammation (ASH 2024) - "Treatment of ECs with non-specific TMEM16 inhibitors also inhibited release of ECEVs and EV PCA (p<0.001 for CaCCinh-A01 and p<0.0001 for benzbromarone and niclosamide)...Mouse models suggest that TMEM16E and 16F are involved in the host-inflammatory response via release of procoagulant EVs from ECs. TMEM16E may regulate exosome formation at the endosomal level whereas 16F may regulate exosome release at the plasma membrane."

Cardiovascular • Inflammation • ANO 5 • ANO6 • CD31 • CD63 • CD9 • CDH5 • PECAM1

Repurposing Niclosamide for COVID-19: Synergistic Strategies of Nanotechnology and Novel Materials to Enhance Antiviral Efficacy. (PubMed, Microb Pathog) - "Additionally, we discuss the latest clinical trial outcomes of niclosamide. Looking ahead, with the ongoing advancements in material synthesis, the synergistic integration of nano-hybridization and innovative material systems for niclosamide is poised to become a pivotal tool in epidemiological management and combating viral threats, providing an innovative, accessible, and cost-effective solution for pandemic control."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases

Evaluation of the inhibitory effects of emodin on Neospora caninum invasion and proliferation in vitro. (PubMed, Int J Parasitol Drugs Drug Resist) - "caninum effects of emodin in Vero cells, MDBK cells, macrophages, as well as the combined effects of emodin and niclosamide in Vero cells, were further verified using qPCR or Giemsa staining...However, the inhibitory effects of emodin on N. caninum invasion and proliferation were not significantly altered in Mlkl-/- macrophages. In conclusion, emodin inhibited N. caninum infection may through a necroptosis-independent mechanism by directly targeting the parasite, highlighting its potential as a therapeutic candidate for neosporosis."

Journal • Preclinical • Infectious Disease

A bibliometric analysis and systematic review of drug repurposing against drug-resistant ESKAPE pathogens: a particular focus on Pseudomonas aeruginosa. (PubMed, Front Microbiol) - "Repurposed agents such as niclosamide and mitomycin C exhibited antibacterial activity through mechanisms including membrane permeability disruption, quorum sensing inhibition, and biofilm suppression. Future efforts should emphasize in vivo validation, clinical trials, and innovative delivery systems to accelerate clinical application. https://www.crd.york.ac.uk/prospero/, identifier CRD420251053437."

Journal • Review

PDZ-binding kinase as a prognostic biomarker for pancreatic cancer: a pan-cancer analysis and validation in pancreatic adenocarcinoma cells (PubMed, Nan Fang Yi Ke Da Xue Xue Bao) - "PBK is a key regulator of pancreatic cancer and interacts with NCAPG2 to promote tumor progression, suggesting its value as a potential biomarker and therapeutic target for pancreatic cancer."

Biomarker • IO biomarker • Journal • Pan tumor • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • CAPG • NCAPG2 • PBK

Advancing Medulloblastoma Treatment: Molecular Mechanisms, Drug Repurposing, and Precision Therapies. (PubMed, Mol Diagn Ther) - "Drug repurposing offers a promising strategy to accelerate treatment availability by utilizing US Food and Drug Administration-approved agents, including niclosamide, itraconazole, and arsenic trioxide, to target critical oncogenic pathways and overcome therapeutic resistance. Emerging technologies, including nanotechnology-based delivery systems, CRISPR-mediated gene editing, and chimeric antigen receptor-T cell therapies, hold significant potential for transforming medulloblastoma treatment paradigms but require further refinement to address toxicity, off-target effects, and biomarker development. Advancing innovative, less toxic therapeutic strategies through the integration of molecular diagnostics and precision therapies is essential to improving survival outcomes and quality of life for children with medulloblastomas."

Journal • Review • Brain Cancer • CNS Tumor • Medulloblastoma • Oncology • Pediatrics • Solid Tumor

Novel niclosamide stearate prodrug therapeutic shows potential efficacy against naturally occurring canine osteosarcoma in a clinical feasibility study. (PubMed, Am J Vet Res) - "Four cycles of IV carboplatin (300 mg/m2, IV, q 3 wk) followed by 4 cycles of the experimental mNSPT (10 mg/kg, IV, weekly). The results support further translational investigation of this novel therapeutic approach to OS treatment in a randomized, prospective phase III study in dogs and, if successful, ultimately in OS patients. These results suggest that niclosamide-when transformed into the highly bioavailable NSPT-may have potential as a novel therapeutic agent for treating OS."

Journal • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

Engineered Niclosamide Loaded Nanofiber Platforms for Enhanced Antibacterial and Anticancer Efficacy. (PubMed, ACS Appl Bio Mater) - "A marked decrease in cell viability was observed when the cells were treated with niclosamide-loaded nanofibers. Collectively, our findings demonstrate that niclosamide-loaded PEO-PCL nanofibers are a promising and efficient drug delivery system with potential applications in antimicrobial and anticancer therapies."

Journal • Infectious Disease • Oncology

Environmental Impact Assessment for Snail Control as a Schistosomiasis Elimination Strategy in Rwanda (ASTMH 2025) - "Niclosamide was identified as the preferred molluscicide for focal application, following World Health Organization dosage guidance (6–8 g/L)...This provides a critical foundation for piloting snail control interventions in Rwanda's endemic areas. The findings will inform national strategy development and donor-supported programming, while contributing operational evidence to integrated vector management efforts across the region."

Late-breaking abstract • Infectious Disease

Efficacy of Anthelmintics and Genetic Resistance Markers of Benzimidazoles in Human and Canine Hookworms in Bono East Region, Ghana (ASTMH 2025) - "Niclosamide showed superior efficacy and may serve as a viable alternative treatment. This evidence calls for immediate action to overhaul current treatment protocols, incorporate resistance monitoring strategies, and adopt a One Health approach to controlling hookworm infections in both human and animal populations."

Clinical • Anemia • Eosinophilia • Hematological Disorders • Infectious Disease

Impact of Chemical Snail Control on Intermediate Host Snail Populations for Urogenital Schistosomiasis Elimination in Pemba, Tanzania: Findings of a 3‑Year Intervention Study (ASTMH 2025) - "Repeated niclosamide application reduced the number of Bulinus in WBs, but snails often recurred after one or multiple treatments. While chemical mollusciciding can reduce snail numbers, to fully break S. haematobium transmission, timely diagnosis and treatment of infected humans, access to clean water, sanitation, and health communication remain of prime importance."

Clinical • Infectious Disease

Niclosamide nanoparticles as a novel adjuvant reverse colistin resistance via multiple mechanisms against multidrug-resistant Salmonella infections. (PubMed, Microbiol Spectr) - "Dose-response analysis shows that niclosamide has extremely high resistance reversal efficiency within a relatively low concentration range. The development of the new dosage form of NCL@mPEG-PLGA-NPs will lay a scientific foundation for the clinical application of colistin adjuvants and the development of drug delivery systems."

Journal • Infectious Disease

Efficacy of topical Ivermectin in controlling human Demodex infestation: Evidence from systematic review and meta-analysis. (PubMed, Parasite Epidemiol Control) - "While new therapies like lotilaner, niclosamide, and berberine show promise against D. folliculorum, ivermectin remains widely used for its strong antiparasitic and anti-inflammatory effects. However, the potential for mite repopulation after treatment underscores the importance of ongoing monitoring. Study heterogeneity and the limited number of included trials warrant cautious interpretation of the findings."

Journal • Retrospective data • Dermatology • Dry Eye Disease • Ocular Inflammation • Ophthalmology • Rosacea

Mito-Specific "Trojan Horse" Nanotherapy: Synergistic Antitumor Immunotherapy via Dual Modulation Mitochondrial Metabolism and Glycolysis. (PubMed, ACS Nano) - "Herein, we developed a mito-specific "Trojan Horse" nanoplatform (2-pN@LNPs) coloaded with Niclosamide (Nic) and 2-deoxy-d-glucose (2-DG) to attack key metabolism pathways and synergistically ignite pyroptosis for restoring antitumor immunity. Moreover, the synergistic treatment regimen can promote cytotoxic and helper T cells (CD8+/CD4+ T cells) recruitment and M1-type macrophage polarization, facilitating the establishment of a boost in immunological memory to prevent recurrence and metastasis. Overall, this work provides a robust strategy targeting metabolism through mitochondrial uncoupling and glycolysis inhibition, which can effectively improve the antitumor effect, inhibit lung metastasis, and help modulate antitumor immunity."

Journal • Metabolic Disorders • Oncology • CD4 • CD8

Exploratory high-throughput screening of repurposed drugs for canine lymphoid malignancies. (PubMed, BMC Vet Res) - "This exploratory screening study identified clinically approved drugs with available pharmacokinetic data as candidate therapeutic agents for the treatment of canine lymphoid malignancies. Based on this study, further studies are warranted to validate the in vivo efficacy and elucidate the underlying mechanisms of candidate drugs in canine lymphoid malignancies."

Journal • Hematological Malignancies • Lymphoma • Oncology